<DOC>
	<DOCNO>NCT00740922</DOCNO>
	<brief_summary>The purpose study retrospectively evaluate safety sterile becaplermin gel compare sterile placebo gel treatment 12 month last dose administer 1 2 double-blind trial [ neither physician patient know name study drug ( PDGF-DBFT-003 PDGF-DBFT-005 ] .</brief_summary>
	<brief_title>Evaluation Safety Follow-up Becaplermin Placebo Gel Following Treatment Chronic , Full Thickness Diabetic Ulcers</brief_title>
	<detailed_description>This single-visit , retrospective study design evaluate long-term safety becaplermin gel 100 mcg/g versus placebo gel . Patients previously enrol protocol PDGF-DBFT-003 PDGF-DBFT-005 evaluate single-study visit retrospective safety data collect . Recurrence data Target Ulcer also obtain . The maximum number patient study sum patient enrol 2 previous trial . The investigator make every effort contact patient enrol previous double-blind trial order get follow-up information many patient possible . If patient decease , cause death , know , collect investigator ( permitted local authority ) . After evaluation entrance criterion , demographic data , significant new intercurrent illness , current medication profile , therapies receive treatment diabetic neuropathic foot ulcer surgery last 12 month collect record . A questionnaire use investigational staff elicit patient information . At visit , complete physical examination do ( special attention give assess presence malignancy ) , foot carefully examine footwear assess . The site Target Ulcer treat previous double-blind trial assess independent dermatologist.and photograph heel , back , inside outside surface foot , well distance photograph foot , take . Parameters major change general health , ( i.e. , hospitalization , major illness , past surgery ) , past well present history malignant disease carefully assess . Of primary interest examination previously treat ulcer site ( ) Target Ulcer limb general , recurrence and/or new ulceration ; treatment outcomes ; relevant change previously treat ulcer surround skin . Observational study - No study drug administer</detailed_description>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Patients require satisfy follow criterion enter study : give write informed consent performance studyrelated procedure , decease , cause death , know , collect investigator ( permitted local authority ) Received least 1 dose study medication 1 doubleblind trial PDGFDBFT003 PDGFDBFT005 postbaseline data A minimum 12 month elapse since last study drug dose 1 doubleblind trial PDGFDBFT003 PDGFDBFT005 Patients meet follow criterion exclude participate study : Patients unwilling participate Patients , despite multiple documented effort , could contact ( investigator ask try least 3 time contact patient patient 's representative parent mail phone )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Becaplermin gel</keyword>
	<keyword>Target Ulcer</keyword>
	<keyword>Retrospective Studies</keyword>
	<keyword>Diabetic Foot</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Long-Term Safety</keyword>
	<keyword>Topical Administration</keyword>
</DOC>